In this work, sensitive detection of dengue virus type 2 E-proteins (DENV-2 E-proteins) was performed in the range of 0.08 pM to 0.5 pM. The successful DENV detection at very low concentration is a matter of concern for targeting the early detection after the onset of dengue symptoms. Here, we developed a SPR sensor based on self-assembled monolayer/reduced graphene oxide-polyamidoamine dendrimer (SAM/NH 2 rGO/PAMAM) thin film to detect DENV-2 E-proteins. Surface characterizations involving X-ray diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR) confirms the incorporation of NH 2 rGO-PAMAM nanoparticles in the prepared sensor films. The specificity, sensitivity, binding affinity, and selectivity of the SPR sensor were then evaluated. Results indicated that the variation of the sensing layer due to different spin speed, time incubation, and concentration provided a better interaction between the analyte and sensing layer. The linear dependence of the SPR sensor showed good linearity (R 2 = 0.92) with the lowest detection of 0.08 pM DENV-2 E-proteins. By using the Langmuir model, the equilibrium association constant was obtained at very high value of 6.6844 TM −1 (R 2 = 0.99). High selectivity of the SPR sensor towards DENV-2 E-proteins was achieved in the presence of other competitors. Dengue virus (DENV) is the most common arthropod-borne viral disease that poses a serious global problem. According to World Health Organization (WHO), the dengue virus is the leading cause of death of 22 000, annually. As of today, the need for hospitalization and medical treatment are constantly dense due to the fact that 390 million people in the world are still infected with DENV 1. Its four distinct serotypes (DENV-1. DENV-2, DENV-3, and DENV-4) are capable of causing a range of clinical symptoms ranging from mild fevers to the severe dengue haemorrhagic fever (DHF) and be potentially life-threatening 2-10. Despite its large burden to human health, no effective vaccine and antiviral therapy are available for the virus 11,12. Early treatment for DENV is only by maintaining the body fluid of the patient, as it is critical in fighting the severe symptoms of DENV 13,14. Hence, an early, rapid, and accurate diagnosis at the onset of infection is the demand of the day in the most epidemic settings. Present discoveries in dengue diagnostics that can help in the early diagnosis are targeting the host-virus itself. DENV consists of a single-stranded positive-sense RNA virus that encodes 10 different types of proteins. Seven of